
Sign up to save your podcasts
Or


An alarming rise in sexually transmitted infections like chlamydia, gonnorhea, and syphilis in the US calls for new prevention and treatment tactics. Dr. Matthew Hamill, a Johns Hopkins clinical researcher specializing in HIV and STIs, talks with Stephanie Desmon about DoxyPEP, or the use of antibiotic doxycycline after sexual contact. They discuss its effectiveness and availability, use in the context of antibiotic resistance, and why DoxyPEP isn't a silver bullet in the prevention of STIs.
By The Johns Hopkins Bloomberg School of Public Health4.6
618618 ratings
An alarming rise in sexually transmitted infections like chlamydia, gonnorhea, and syphilis in the US calls for new prevention and treatment tactics. Dr. Matthew Hamill, a Johns Hopkins clinical researcher specializing in HIV and STIs, talks with Stephanie Desmon about DoxyPEP, or the use of antibiotic doxycycline after sexual contact. They discuss its effectiveness and availability, use in the context of antibiotic resistance, and why DoxyPEP isn't a silver bullet in the prevention of STIs.

43,673 Listeners

40 Listeners

5 Listeners

26 Listeners

5 Listeners

260 Listeners

56,649 Listeners

493 Listeners

9 Listeners

45 Listeners

94 Listeners

16,356 Listeners

16 Listeners

4,773 Listeners

2 Listeners

4,482 Listeners

389 Listeners

6,554 Listeners

25 Listeners

6,402 Listeners

231 Listeners

67 Listeners

166 Listeners

110 Listeners